FDA to Build $600 Million Campus

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

ROCKVILLE, Md--By the year 2003, the FDA hopes to be settled into its new 539-acre home in Clarksburg, Md, a small farming community about 15 miles north of the agency's main Rockville headquarters.

ROCKVILLE, Md--By the year 2003, the FDA hopes to be settled intoits new 539-acre home in Clarksburg, Md, a small farming communityabout 15 miles north of the agency's main Rockville headquarters.

The project should receive final approval in June after completionof an environmental impact study, and construction is scheduledto begin next year. More than 6,000 FDA workers, now scatteredamong dozens of sites, will move to the Clarksburg campus. Accesswill be from an existing interstate highway, but the new sitewill not be near public transportation.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content